// App-Quantinova.ai

: A Phase 2 Study of Ruxolitinib with Chemotherapy in Children with Philadelphia Chromosome-like Acute Lymphoblastic Leukemia (AALL1521/INCB18424-269): Biologic Characteristics and Minimal Residual Disease Response of Patients with Non-CRLF2-Rearranged JAK Pathway Alterations

Researchers

Presenter

  • Sarah K Tasian

Principal Investigators

  • Deborah S Hunter

  • I-Ming L Chen

  • Richard C Harvey

  • Andrew J. Carroll

  • Elizabeth Wagner

  • Shalini C Reshmi

  • Michael J Borowitz

  • Brent L. Wood

  • Jeannie Daniel

  • Meenakshi Devidas

  • Elizabeth A. Raetz

  • Stephen P. Hunger

  • Albert Assad

  • Mignon L. Loh

Medical Centers

  • Department of Pediatrics and Center for Childhood Cancer Research, Children's Hospital of Philadelphia and the Perelman School of Medicine at The University of Pennsylvania, Philadelphia, PA

  • Division of Pediatric Hematology and Oncology, Stephen D. Hassenfeld Children's Center for Cancer and Blood Disorders, NYU Langone Health, New York, NY

  • Division of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA

  • Department of Global Pediatric Medicine, St Jude Children's Research Hospital, Memphis, TN

  • Division of Hematology, Oncology, BMT, and Cellular Therapies, Seattle Children's Hospital, Seattle, WA

  • Department of Pediatrics and Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA

  • Departments of Pathology and Oncology, Johns Hopkins Hospital, Baltimore, MD

  • Department of Pathology and Laboratory Medicine, Nationwide Children's Hospital, Columbus, OH

  • University of New Mexico Cancer Center, Albuquerque, NM

  • Department of Genetics, University of Alabama at Birmingham, Birmingham, AL

  • Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, Los Angeles, CA

Locations

  • United States

Companies

  • Incyte Corporation

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute lymphoblastic leukemia

Biomarkers

  • Breakpoint Cluster Region

  • Janus kinase

Drug/Treatment

  • Ruxolitinib phosphate

Outcome

  • N/A

Study Design

  • Cohort

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved